浙江交科(002061.SZ):聯合體簽署26.75億元中標項目合同
格隆匯1月8日丨浙江交科(002061.SZ)公佈,公司於2019年11月9日、20日分別在巨潮資訊網披露了《關於下屬公司中標的提示性公告》和《關於下屬公司收到中標通知書的公告》,招標人滬昆鐵路客運專線浙江有限責任公司確認中鐵五局集團有限公司、浙江交工集團股份有限公司聯合體為新建湖州至杭州西至杭黃高鐵連接線站前工程HHLJXZQ-4標段施工中標單位。
近日,聯合體成員與滬昆鐵路客運專線浙江有限責任公司(以下簡稱“滬昆鐵路浙江有限公司”或“發包人”)簽署了《合同協議書》,合同金額為人民幣26.75億元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.